1、Konstantinides SV,MeyerG,Becattini C,et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society ERS: the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology(ESC)[J]. Eur Heart J,2019,54(3):1901647
2、王秋桐, 吴爽, 刘颖, 王晓宇, 陈玲 & 赵瑞.(2020). 阿替普酶与尿激酶初始溶栓治疗中老年急性肺栓塞患者治愈率与安全性的 Meta 分析. 实用心脑肺血管病杂志 (07),88-953、Piazza G,Goldhaber SZ. Fibrinolysis for acute pulmonary embolism [J]. Vasc Med,2010,15( 5) : 419-4284、Zhang Xue -xia.The Efficacy and Safety of Alteplase and Urokinase in the Treatment of Acute Pulmonary Embolism with Thrombolysis[J].Chinese and foreigr medical treatment, 2018(18):122-1245、Li, Z.P.et al.[Chronic effects of 100 mg/2 hours recombinant tissue-type plasminogen activator therapy regimen for patients with acute pulmonary thromboembolism]. Zhonghua Xin Xue Guan Bing Za Zhi, 2013. 41(3): p. 224-86、Konstantinides, S.V.et al. Corrigendum to: 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J, 2015. 36(39): p.26427、Wang, C.et al. Efficacy and Safety of Low Dose Recombinant Tissue-Type Plasminogen Activator for the Treatment of Acute Pulmonary Thromboembolism. Chest, 2010. 137(2): p. 254-2628、Sharifi M,Bay C,Skrocki L,et al. Moderate pulmonary embolism treated with thrombolysis(from the 'MOPETT' Trial)[J]. Am J Cardiol,2013,111(2):273-2779、KISER T H,BURNHAM E L,CLARK B,et al.Half-dose versus full-dose alteplase for treatment of pulmonary embolism[J].Crit Care Med,2018,46(10):1617-1625